The disposition of [¹⁴C]-labelled benazepril HC1 in normal adult volunteers after single and repeated oral dose

References

• Botta L., Gerber H. U., Schmid K. Measurement of radioactivity in biological experiments. Drug Fate and Metabolism, E. R. Garrett, J. L. Hirtz. Marcel Dekker, New York 1985; Vol. 5: 99–134
   Google Scholar
• Caldwell J., Hutt A. J. Methodology for the isolation and characterisation of conjugates of xenobiotic carboxylic acids. Progress in Drug Metabolism, J. W. Bridges, L. F. Chasseaud. Taylor & Francis, London 1986; Vol. 9: 11–51
   Google Scholar
• Chaudhuri N. K., Patera R., Markus B., Sung M.-S. Synthesis of 14C-labeled 3-[‘1-ethoxycarbonyl-3-phenyl-(1S)-propyl’-amino]-2,3,4,5-tetrahydro-2-oxo-1-(3S)-benzaze-pine-1-acetic acid hydrochloride (‘14C’CGS 14 824 A). Journal of Labelled Compounds and Radiopharmaceuticals 1987; 24: 1177–1184
   Web of Science ®Google Scholar
• Chen D. S., Dotson R. A., Burrel R. D., Watkins B. E. Two potent angiotensin-converting enzyme (ACE) inhibitors: CGS 14 824 A and CGS 14 831. Pharmacologist 1983; 25: 240
   Google Scholar
• Dieterle W., Ackermann R., Kaiser G. Pharmacokinetics of benazeprilat after intravenous administration in healthy volunteers. European Journal of Clinical Pharmacology 1989; 36(Suppl. A)303
   Google Scholar
• Faed E. M. Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metabolism Reviews 1984; 15: 1213–1249
   PubMed Web of Science ®Google Scholar
• Francis R. J., Brown A. N., Kler L., Fasanella D'Amore T., Nussberger J., Waeber B., Brunner H. R. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. Journal of Cardiovascular Pharmacology 1987; 9: 32–38
   PubMed Web of Science ®Google Scholar
• Hurley M. E., Watters J. T., Benz J. R., Maker T. F., Ivankoe L. D., Ribeiro L. G. T. CGS 14 824 A, a new ACE inhibitor for mild to moderate hypertension. Journal of Clinical Pharmacology 1987; 27: 718
   Google Scholar
• Kaiser G., Ackermann R., Dieterle W., Dubois J. P. Determination of a new angiotensin converting enzyme inhibitor and its active metabolite in plasma and urine by gas chromatographymass spectrometry. Journal of Chromatography 1987; 419: 123–133
   PubMed Web of Science ®Google Scholar
• Kaiser G., Ackermann R., Brechbuehler S., Dieterle W. Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril HC1 (CGS 14 824 A) in healthy volunteers after single and repeated administration. Biopharmaceutics and Drug Disposition 1989; 10: 365–376
   PubMed Web of Science ®Google Scholar
• Kaiser G., Ackermann R., Gschwind H. P., James I. M., Sprengers D., McIntyre N., Defalco A., Holmes I. B. The influence of hepatic cirrhosis on the pharmacokinetics of benazepril hydrochloride. Biopharmaceutics and Drug Disposition 1990; 11: 753–764
   PubMed Web of Science ®Google Scholar
• Lees K. R., Kelman A. W., Reid J. L., Whiting B. Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding. Journal of Pharmacokinetics and Biopharmaceutics 1989; 17: 529–550
   PubMedGoogle Scholar
• Miller D., Hopkins M. F., Tonnesen S. T., Watkins B. E. Antihypertensive assessment of CGS 14 824 A, an orally effective angiotensin converting enzyme (ACE) inhibitor. Pharmacologist 1983; 25: 102
   Google Scholar
• Schaller M. D., Nussberger J., Waeber B., Bussien J. P., Turini G. A., Brunner H., Brunner H. R. Haemodynamic and pharmacological effects of the converting enzyme inhibitor CGS 14 824 A in normal volunteers. European Journal of Clinical Pharmacology 1985; 28: 267–272
   PubMed Web of Science ®Google Scholar
• Till A. E., Gomez H. J., Hichens M., Bolognese J. A., McNabb W. R., Brooks B. A., Noormohamed F., Lant A. F. Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. Biopharmaceutics and Drug Disposition 1984; 5: 273–280
   PubMed Web of Science ®Google Scholar
• Ulm E. U., Hichens M., Gomez H. J., Till A. E., Hand E., Vassil T. C., Biollaz J., Brunner H. R., Schelling J. L. Enalapril maleate and a lysine analogue (MK-521): disposition in man. British Journal of Clinical Pharmacology 1982; 14: 357–362
   PubMed Web of Science ®Google Scholar
• Waeber G., Fasanella D'Amore T., Nussberger J., Waeber B., Brunner H. R. Effects on blood pressure and the renin-angiotensin system of repeated doses of the converting enzyme inhibitor CGS 14 824 A. European Journal of Clinical Pharmacology 1987; 31: 643–646
   PubMed Web of Science ®Google Scholar
• Wagner J., Sulc M. Binding of diclofenac-Na (Voltaren) to serum proteins of different species and interactions with other drugs in protein binding. Aktuelle Rheumatologie 1979; 4: 153–158
   Web of Science ®Google Scholar
• Waldmeier F., Faigle J. W., Schmid K. Disposition and biotransformation of the ACE inhibitor trial drug CGS 14 824 A in rat, dog, baboon and man. Poster presented at the 10th European Drug Metabolism Workshop, GuildfordUK, 1986; 45, Abstracts
   Google Scholar
• Waldmeier F., Schmid K. Disposition of ‘14C’-benazepril hydrochloride in rat, dog and baboon: absorption, distribution, kinetics, biotransformation and excretion. Arzneimittel-Forschung Drug Research 1989; 39: 62–67
   PubMed Web of Science ®Google Scholar
• Witte P. U., Irmisch R., Hajdu P., Metzger H. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects. European Journal of Clinical Pharmacology 1984; 27: 577–581
   PubMed Web of Science ®Google Scholar